Back to Search
Start Over
Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling
- Source :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 10 (2016)
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- BackgroundExperimental uremic cardiomyopathy causes cardiac fibrosis and is causally related to the increased circulating levels of the cardiotonic steroid, marinobufagenin (MBG), which signals through Na/K‐ATPase. Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR) implicated in the progression of many different forms of renal disease. Given that Na/K‐ATPase signaling is known to stimulate the mTOR system, we speculated that the ameliorative effects of rapamycin might influence this pathway. Methods and ResultsBiosynthesis of MBG by cultured human JEG‐3 cells is initiated by CYP27A1, which is also a target for rapamycin. It was demonstrated that 1 μmol/L of rapamycin inhibited production of MBG in human JEG‐2 cells. Male Sprague‐Dawley rats were subjected to either partial nephrectomy (PNx), infusion of MBG, and/or infusion of rapamycin through osmotic minipumps. PNx animals showed marked increase in plasma MBG levels (1025±60 vs 377±53 pmol/L; P
Details
- Language :
- English
- ISSN :
- 20479980
- Volume :
- 5
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9ab7f2b8d1104389af36bfc972a96b23
- Document Type :
- article
- Full Text :
- https://doi.org/10.1161/JAHA.116.004106